Peritoneal metastasis (PM) is the primary pattern of metastasis for certain types of tumors, such as those of the appendix, ovary, and peritoneal mesothelioma. Traditionally, PM has been considered incurable with a poor prognosis. However, recent advancements in our understanding of the biology of peritoneal disease and the introduction of modern chemotherapeutic drugs and cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have provided new hope for patients with PM. CRS/HIPEC is now an accepted treatment option, although careful patient selection is necessary due to its high morbidity and mortality rates. Additionally, novel treatments such as targeted therapies, immunotherapy, and drug delivery systems based on nanotechnology are being explored for the treatment of PM. The future of PM treatment holds promise with advancements in laparoscopy, robotic surgery, molecular profiling, immunotherapy, and early detection methods. [Extracted from the article]